Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.73 CAD
Change Today +0.03 / 4.29%
Volume 4.4K
ONC On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 9:36 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONC) Snapshot

Open
C$0.73
Previous Close
C$0.70
Day High
C$0.73
Day Low
C$0.73
52 Week High
03/3/15 - C$1.74
52 Week Low
10/10/14 - C$0.45
Market Cap
82.4M
Average Volume 10 Days
107.3K
EPS TTM
C$-0.16
Shares Outstanding
117.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONC)

oncolytics biotech inc (ONC) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONC) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONC) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Founded in 1998

oncolytics biotech inc (ONC) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$538.0K
Chief Financial Officer
Total Annual Compensation: C$284.2K
Chief Operating Officer and Director
Total Annual Compensation: C$370.5K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: $316.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $143.0K
Compensation as of Fiscal Year 2014.

oncolytics biotech inc (ONC) Key Developments

Oncolytics Biotech Inc. Announce Resignation of Linda Hohol from the Board of Directors with Effect from August 5, 2015

Oncolytics Biotech Inc. announced that Linda Hohol resigned from the Board of Directors of the company effective August 5, 2015. Ms. Hohol has served as a Director since June 2014.

Oncolytics Biotech Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Oncolytics Biotech Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, loss before income taxes was $3,849,487 compared to $4,714,617 a year ago. Net loss was $3,850,258 compared to $4,718,163 a year ago. Net cash used in operating activities was $5,118,284 compared to $5,780,235 a year ago. Capital expenditures were $17,657 compared to $1,239 a year ago. Basic and diluted loss per common share was $0.03 compared to $0.05 a year ago. For the six months, loss before income taxes was $7,401,325 compared to $10,196,218 a year ago. Loss before income taxes was $58 million compared to loss before income taxes $306 million a year ago. Net loss was $7,402,096 compared to $10,203,614 a year ago. Net cash used in operating activities was $7,865,473 compared to $11,944,313 a year ago. Capital expenditures were $29,597 compared to $17,219 a year ago. Basic and diluted loss per common share was $0.07 compared to $0.12 a year ago.

Oncolytics Biotech Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 02:30 PM

Oncolytics Biotech Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 02:30 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Bradley G. Thompson, Executive Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONC:CN C$0.73 CAD +0.03

ONC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONC.
View Industry Companies
 

Industry Analysis

ONC

Industry Average

Valuation ONC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.